Previous Close | 1.3300 |
Open | 1.3200 |
Bid | 1.2700 x 1400 |
Ask | 1.3100 x 1100 |
Day's Range | 1.2693 - 1.3300 |
52 Week Range | 1.2100 - 3.5500 |
Volume | |
Avg. Volume | 325,083 |
Market Cap | 92.776M |
Beta (5Y Monthly) | 0.91 |
PE Ratio (TTM) | 14.11 |
EPS (TTM) | 0.0900 |
Earnings Date | May 02, 2024 - May 06, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 13.00 |
Subscribe to Yahoo Finance Plus to view Fair Value for PLX
Protalix BioTherapeutics, Inc. (AMEX:PLX) Q4 2023 Earnings Call Transcript March 14, 2024 Protalix BioTherapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.07 EPS, expectations were $-0.03. Protalix BioTherapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning, […]
By John Vandermosten, CFA NYSE:PLX READ THE FULL PLX RESEARCH REPORT Full Year 2023 Financial and Operational Review Protalix Biotherapeutics, Inc. (NYSE:PLX) announced full year 2023 financial and operational results in a March 14th, 2024 press release and filing of Form 10-K . The reports were followed by a conference call which discussed recent achievements, regulatory updates and financial
PLX Sees Regulatory Approvals and Commercial Progress Amidst Financial Growth